



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX	
Name of listed issuer:	Oceania Healthcare Limited
Date this disclosure made:	23 April 2021
Date of last disclosure:	2 March 2021

Director or senior manager giving disclosure

Full name(s):	Alan Isaac
Name of listed issuer:	Oceania Healthcare Limited
Name of related body corporate (if applicable):	N/A
Position held in listed issuer:	Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)

Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Registered and beneficial owner of shares
For that relevant interest -	
Number held in class before acquisition or disposal:	114,947
Number held in class after acquisition or disposal:	130,286
Current registered holder(s):	New share issue
Registered holder(s) once transfers are registered:	Alan Raymond Isaac

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	N/A
Class of underlying financial products:	N/A

Details of affected derivative -

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price specified in the terms of the derivative (if any):	N/A

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

N/A

For that derivative: -

Parties to the derivative:

N/A

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

1

Details of transactions requiring disclosure -

Date of transaction:

16 April 2021

Nature of transaction:

Acquisition of 15,339 ordinary shares in Oceania Healthcare Limited in the Retail Offer announced to the market on 23 March 2021.

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$19,628.67

Number of financial products to which the transaction related:

15,339

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details -

Whether relevant interests were acquired or disposed of during a closed period:

Yes

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Yes

Date of the prior written clearance (if any):

23 March 2021

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Ordinary shares

Nature of relevant interest:

Registered and beneficial owner of shares

For that relevant interest -

Number held in class:

15,000

Current registered holder(s):

Mary Isaac

Class of quoted financial products:

Ordinary shares

Nature of relevant interest:

Registered and beneficial owner of shares

For that relevant interest -

Number held in class:

155,409

Current registered holder(s):

Alan Raymond Isaac, Andrew John Dinsdale and Alasdair Donald McBeth as trustees of Isaac Family Trust

For a derivative relevant interest -

Type of derivative:

N/A

Details of derivative -

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

N/A

A statement as to whether the derivative is cash settled or physically settled:

N/A

Maturity date of the derivative (if any):

N/A

Expiry date of the derivative (if any):

N/A

The price's specified terms (if any):

N/A

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

N/A

For that derivative relevant interest:

Parties to the derivative:

N/A

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A

Certification


I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:



Date of signature:

23 April 2021

Name and title of authorised person:

Anna Thorburn
General Counsel & Company Secretary